NextCure Share Price

NextCure Share Price

NASDAQ: NXTC | Healthcare
$0.00
-$6.82 (--%)
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

NextCure Stock Performance

Open
N/A
Prev. Close
$6.82
Circuit Range
N/A
Day Range
N/A
Year Range
$1.55 - $15.61
Volume
N/A
Average Traded
N/A

NextCure Share Price Chart

Line chart of the NextCure price trend over the selected period. The price fell overall, ranging from 6.77 to 7.25, ending at 6.82.
$0.00$0.00
L
Show Current Price
H

NextCure Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-8.95
Revenue (TTM)
$0.00
Return On Equity (TTM)
-744.50%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
27.44%

NextCure Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$9.44-$9.80-$14.89-$6.85
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-3.81%-51.94%54.00%

NextCure Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$74.73-$62.72-$55.65-$55.84
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A16.07%11.27%-0.34%

NextCure Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets6.449.0515.3120.18
Current Assets43.7571.81112.73163.98
Total Assets50.1880.86128.04184.16
Non Current Liabilities4.675.816.737.5
Current Liabilities10.579.576.889.13
Total Liabilities15.2415.3913.6216.63
Shareholders' Equity34.9465.47114.42167.53

NextCure Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-49.61-40.81-52.97-53.89
Investing25.5655.3139.2767.98
Financing22.310.140.150.2

Corporate Actions

Split
Ex-date: 14 Jul 2025

About NextCure

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

NextCure Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$5.71
$6.82
+4.85%
Oct 2026
$5.13
$6.50
+27.70%
Sep 2026
$6.51
$5.09
-16.35%
Aug 2026
$4.32
$6.08
+48.41%
Jul 2026
$1.85
$4.10
+149.24%
Jun 2026
$5.77
$1.65
-73.60%
May 2026
$9.80
$6.23
-33.37%
Apr 2026
$11.28
$9.35
-10.40%
Mar 2026
$12.19
$10.44
-20.95%
Feb 2026
$11.14
$13.20
+20.55%
Jan 2026
$13.43
$10.95
-23.80%
Dec 2025
$12.04
$14.37
+2.35%

NextCure Share Price FAQs